PublicationsAbstracts:Bloom FL, Spangler DL, Rhoades RB, Cohan RH, Wittig HJ. Treatment of chronic perennial rhinitis with new topical steroid spray (Flunisolide) a double-blind crossover study. American Academy of Allergy, San Juan, March, 1976.
Spangler DL, Bloom FL, Wittig HJ. Pharmacokinetics of long-acting theophylline drugs. American Academy of Allergy, San Juan, March, 1976.
Bloom FL, Spangler DL, et al. Imported fire ant rapid hyposensitization. American Academy of Allergy, Phoenix, Arizona, February, 1978.
Tinkelman D, Vanderpool G, Carroll S, Spangler D. Compliance differences with administration of theophylline at six and twelve hour intervals. J Allergy Clin Immunol 1980;65(3):178.
Beaucher W, Levy M, Schwartz H, Spangler D. A multiclinic comparison of two sustained released theophyllines in reversible airway disease. 37th Annual Scientific Assembly, Anatheim, California October, 1985.
Spangler D, Wilson J. The effect of diet on the efficacy onset and duration of action of procaterol hydrochloride tablets. American Academy of Allergy & Immunology, New Orleans, March, 1986.
Spangler D, Drug and Anaphylaxis Committee. Results of physicians survey for treatment of immunotherapy reactions. American College of Allergy, Asthma & Immunology, Boston, MA November, 1996.
Abelson MB, Spangler D, Giovanoni A. Chemosis is an important diagnostic tool for evaluating new opththalmic anti-allergic agents using the conjunctival allergen challenge model. American College of Allergy, Asthma & Immunology, Chicago, IL November, 1999.
Spangler, DL, Abelson M. Investigation of the nasal and conjunctival mucosa reaction to allergen exposure using the conjunctival and nasal allergen challenge models. American College of Allergy, Asthma & Immunology, New Orleans, LA, November 2003.
Spangler, DL, Abelson M. The ocular & nasal allergic connection. American College of Allergy, Asthma & Immunology, Boston, MA, November, 2004.
Refereed Journals:Bloom FL, Spangler DL, McMichael JE, Wittig HJ, Upson P. Sunshine Station, Florida Camp for Children with Asthma. J Florida Med Assoc 1977;63:710-713.
Bloom FL, Spangler DL et al. Flunisolide aerosol in the treatment of perennial allergic rhinitis. Ann Allergy 1977;38(6):408-412.
Spangler DL et al. Theophylline bioavailability following oral administration of six sustained release preparations. Ann Allergy 1978;40(1):6-10.
Tinkelman D, Vanderpool G, Carroll S, Spangler D. Use of a twelve hour theophylline preparation in chronic adult asthmatics. Ann Allergy 1979;43:155-159.
Tinkelman D, Vanderpool G, Carroll S, Spangler D. Effect of sustained release theophylline on exercise induced bronchospasm. Presented as a scientific exhibit at the 36th Annual Congress American College of Allergists, Bal Harbour, Florida, January, 1980.
Letters to the Editor. Ann Allergy 1978;(6):420.
Letters to the Editor. Ann Allergy 1978;(10):251-242.
Tinkelman D, Vanderpool G, Carroll S, Page G, Spangler D. Compliance differences following administration of theophylline at six and twelve hour intervals. Ann Allergy 1980;(5):44.
Spangler DL, Vanderpool G, Carroll S, Tinkelman D. Terbutaline in the treatment of chronic urticaria. Ann Allergy 1980;(10):45-46.
Spangler DL, Vanderpool G, Carroll S, Tinkelman D. Bioavailability and multiple dose characteristics of a new sustained release theophylline tablet. Ann Allergy 1980;(12):45-46.
Lotner GZ, Vanderpool G, Carroll S, Tinkelman D, Spangler D. Bioavailability of sustained release theophylline granules in applesauce in pediatric asthmatic patients. Ann Allergy 1983;50(1):27.
Tinkelman D, Vanderpool G, Carroll S, Lotner G, Spangler D. Comparison of nebulized terbutaline (TERB) and subcutaneous epinephrine (EPI) in the treatment of acute asthma. Ann Allergy 1983;50(6):398-401.
Tinkelman D, Edelman L, DeCouto J, Maloch L, Spangler D. The effect of diet on the metabolism of long acting theophylline. Ann Allergy 1985;54(4):280-283.
Lotner G, Vanderpool G, Carroll S, Spangler D, Tinkelman D. Use of seralyzer system for theophylline level determination in an office setting. Ann Allergy 1985;55(3):454-457.
Tinkelman D, Webb C, Vanderpool G, Carroll S, Spangler D, Lotner G. The use of Ketotifen in the prophylaxis of seasonal allergic asthma. Ann Allergy 1986;56(3):454-457.
Spangler DL, Lutz CN, Tinkelman DG. The effects of diet on the efficacy onset and duration of action of procaterol hydrochloride tablets. Ann Allergy 1987;58(1):59-62.
Tinkelman DG, DeJong R, Lutz D, Spangler DL. Evaluation of tremor and efficacy of oral procaterol on adult asthmatic patients.
Spangler D, Tinlkelman D. The side effects of beta agonists in children. Am J Asthma Allergy Ped 1989;2(3):172-175.
Spangler D. Review of side effects associated with beta agonists. Ann Allergy 1989;62(1):59-62.
Tinkelman D, DeJong R, Lutz C, Spangler D. Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma. J Allergy Clin Immunol 1990;85(4):719-728.
Spangler D. Review of side effects associated with beta agonists. Allergy Digest 1990;4:22-23.
Spangler D. Nebenwirkungen der Beta-Sympathomimetika. Allergy Digest 1990;5:26-27.
Spangler D. About Nedocromil Sodium “Advise From Your Allergist” column (Submitted for publication to Ann Allergy).
Berdy GJ, Spangler D, Bensch G, Berdy S, Brusatti R. A Comparison of the Relative Efficacy and Clinical Performance of Olopatadine Hydrochloride 0.1% Ophthalmic Solution and Ketotifen Fumarate 0.025% Ophthalmic Solution in the Conjunctival Antigen Challenge Model. Clinical Therapeutics 2000;22(7):826-833.
Abelson, MB, Spangler D, et al. The Diagnosis and Management of Red Eye. Infectious Diseases in Children. 2001:1-15.
Spangler DL, Bensch G, Berdy G. Evaluation of the Efficacy of Olopatadine Hydrochloride 0.1% Ophthalmic Solution and Azelastine HCL 0.05% Ophthalmic Solution in the Conjunctival Allergen Challenge Model. Clinical Therapeutics 2001; 23(8):1272-1280.
Kaiser HB, Rooklin A, Spangler D Capano D. Efficacy of Loratadine Compared with Fexofenadine or Placebo for the Treatment of Seasonal Allergic Rhinitis. Clin Drug Invest 2001;21(8):571-578.
Abelson MB, Spangler D, et al. Comparison of the Efficacy of Combined Fluticasone Propionate and Olopatadine Versus Combined Fluticasone Propionate and Fexofenadine for the Treatment of Allergic Rhinoconjunctivitis Induced by Conjunctival Allergen Challenge. Clinical Therapeutics 2002; 24(7): 1161-1174.
Casale TB, Spangler D, et al. First Do No Harm: Managing Antihistamine Impairment in Patients with Allergic Rhinitis. J Allergy Clin Immunol 2003; 111(5): S835-S842.
Spangler DL, et al. Randomized, Double-Masked Comparison of Olopatadine Ophthalmic Solution, Mometasone Furoate Monohydrate Nasal Spray, and Fexofenadine Hydrochloride Tablets Using the Conjunctival and Nasal Allergen Challenge Models. Clinical Therapeutics 2003; 25(8): 2245-2267.
Spangler, et al. Comparison of Olopatadine Nasal Spray 0.6%, Placebo and Fluticasone Propionate 0.05% in Patients with Seasonal Allergic Rhinitis (SAR) Symptoms. J. Allergy Clin Immunol 2005; 115(2) :518.
Spangler, et al. Efficacy and Central Nervous System Impairment of Newer Generation Prescription Antihistamines in Seasonal Allergic Rhinitis. Southern Medical Journal 2006; 99 (6): 1-7.
Spangler, et al. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Current Eye Research. 2007.
Spangler, D. The Efficacy and Safety of Small–particle-sized ICS Use in Children With Asthma. Reviews and Trends in Respiratory Medicine 2009; 1 (3): 4-11.
Books:Allergic Rhinitis - Current Pediatric Therapy. Wittig HJ, Spangler D. Gellis SS and Kagam BM (eds) Philadelphia, WB Saunders Company 1975.
Other:Poster Exhibit at the 1985 meeting of the American Association for Clinical Immunology and Allergy entitled: Evaluation of Uniphyl Tablets in Reversible Obstructive Airway Disease (ROAD).
Editorial: "Another look at the most frequently cited articles from the Annals of Allergy." Number 1 cited article for 1945-1990 was "Theophylline bioavailability following oral administration of six sustained-release preparations," Spangler DL, Bloom FL, Wittig HJ. Ann Allergy 1993;71:1.
"Advice from your Allergist" column: "Update on Theophylline" Accepted for publication Ann Allergy.
“Contemporary Issues in Management of Ocular Allergy.” Abelson M, Bensch G, Discepola M, Spangler D – Education Slide/Outline Presentation.
Poster Exhibit presented at the November 7-12, 2003 meeting of the American College of Allergy, Asthma & Immunology, New Orleans entitled: “Investigation of the Nasal and Conjunctival Mucosa Reaction to Allergen Exposure Using the Conjunctival and Nasal Allergen Challenge Models.”
Poster Exhibit presented at the January 27-31, 2004 42nd Annual Session of the Western Society of Asthma, Allergy & Immunology, Hualalai, Hawaii entitled: “Ocular administration of anti-allergy, ophthalmic solution aid in management of the nasal symptoms of rhinoconjunctivitis”.
Small Airway Disease in Asthma. Gerold L. Schiebler Lectureship. Presented at the University of Florida College of Medicine, Pediatric Update 2004. October 1-3, 2004.
Poster Exhibit presented at the November 12-17, 2004 Annual Meeting of the American College of Allergy, Asthma & Immunology, Boston, MA entitled: “Impairment with second-generation antihistamines: Evidence from published literature”.
Poster Exhibit presented at the January 23-27, 2005 43rd Annual Session of the Western Society of Allergy, Asthma, & Immunology, Kauai, Hawaii entitled: “Comparison of Fexofenadine HCL 180 mg and Montelukast NA 10 mg vs placebo for seasonal allergic rhinitis: An Allergen exposure unit study”.
Poster Exhibit presented at the January 14-18, 2007 Annual Session of the Western Society of Allergy, Asthma, & Immunology, Maui, Hawaii entitled: “One drop of olopatadine 0.2% is comparable to two drops of olopatadine 0.1% in the prevention of itching associated with allergic conjunctivitis after 24 hours”.
Poster Exhibit presented at the January 21-25, 2008 46th Annual Scientific Session of the Western Society of Allergy, Asthma, & Immunology, Kona, Hawaii entitled: “Comparative Study of Sensory Attributes of Two Antihistamine Nasal Sprays: Olopatadine 0.6% and Azelastine 0.1%”.